instruction:
In this task, you are given text for US Congressional and California state bills, your task is to generate a summary for this bill.
question:
SECTION 1. SHORT TITLE.

This Act may be cited as the ''Depository Institution Community
Development Investments Enhancement Act''.

SEC. 2. TECHNICAL CORRECTIONS.

(a) National Banks.--The first sentence of the paragraph designated
as the ''Eleventh'' of section 5136 of the Revised Statutes of the
United States (12 U.S.C. 24) (as amended by section 305(a) of the
Financial Services Regulatory Relief Act of 2006) is amended by
striking ''promotes the public welfare by benefitting primarily'' and
inserting ''is designed primarily to promote the public welfare,
including the welfare of''.
(b) State Member Banks.--The first sentence of the 23rd paragraph
of section 9 of the Federal Reserve Act (12 U.S.C. 338a) is amended by
striking ''promotes the public welfare by benefiting primarily'' and
inserting ''is designed primarily to promote the public welfare,
including the welfare of''.

SEC. 3. INVESTMENTS BY FEDERAL SAVINGS ASSOCIATIONS AUTHORIZED TO
PROMOTE THE PUBLIC WELFARE.

Section 5(c) of the Home Owners' Loan Act (12 U.S.C. 1464) is
amended--
(1) in paragraph (3)--
(A) by striking subparagraph (A); and
(B) by redesignating subparagraphs (B) and (C), as
subparagraphs (A) and (B), respectively; and
(2) in paragraph (4), by adding at the end the following
new subparagraph:
''(G) Direct investments to promote the public
welfare.--
''(i) In general.--A Federal savings
association may make investments, directly or
indirectly, each of which is designed primarily
to promote the public welfare, including the
welfare of low- and moderate-income communities
or families through the provision of housing,
services, and jobs.
''(ii) Direct investments or acquisition of
interest in other companies.--Investments under
clause (i) may be made directly or by
purchasing interests in an entity primarily
engaged in making such investments.
''(iii) Prohibition on unlimited
liability.--No investment may be made under
this subparagraph which would subject a Federal
savings association to unlimited liability to
any person.
''(iv) Single investment limitation to be
established by director.--Subject to clauses
(v) and (vi), the Director shall establish, by
order or regulation, limits on--
''(I) the amount that any savings
association may invest in any 1
project; and
''(II) the aggregate amount of
investment of any savings association
under this subparagraph.
''(v) Flexible aggregate investment
limitation.--The aggregate amount of
investments of any savings association under
this subparagraph may not exceed an amount
equal to the sum of 5 percent of the capital
stock of the savings association actually paid
in and unimpaired and 5 percent of the
unimpaired surplus of the savings association,
unless--
''(I) the Director determines that
the savings association is adequately
capitalized; and
''(II) the Director determines, by
order, that the aggregate amount of
investments in a higher amount than the
limit under this clause would pose no
significant risk to the affected
Deposit Insurance Fund.
''(vi) Maximum aggregate investment
limitation.--Notwithstanding clause (v), the
aggregate amount of investments of any savings
association under this subparagraph may not
exceed an amount equal to the sum of 15 percent
of the capital stock of the savings association
actually paid in and unimpaired and 15 percent
of the unimpaired surplus of the savings
association.
''(vii) Investments not subject to other
limitation on quality of investments.--No
obligation that a Federal savings association
acquires or retains under this subparagraph
shall be taken into account for purposes of the
limitation contained in section 28(d) of the
Federal Deposit Insurance Act on the
acquisition and retention of any corporate debt
security not of investment grade.
''(viii) Applicability of standards to each
investment.--The standards and limitations of
this subparagraph shall apply to each
investment under this subparagraph made by a
savings association directly and by its
subsidiaries.''.
answer:
Depository Institution Community Development Investments Enhancement Act - Amends the Home Owners' Loan Act to revise requirements for community development investments by federal savings associations.

Authorizes a federal savings association to make investments, directly or indirectly, each of which is designed primarily to promote the public welfare, including the welfare of low- and moderate-income communities or families through the provision of housing, services, and jobs (community development investments).

Permits such investments to be made directly or by purchase of interests in an entity primarily engaged in making such investments.

Prohibits a federal savings association from making an investment which would subject it to unlimited liability to any person.

Requires the Director of the Office of Thrift Supervision to establish: (1) the amount any savings association may invest in any one project; and (2) the aggregate amount of investment of any savings association.

Restricts the aggregate amount of investment of any savings association, subject to specified determinations made by the Director.

Prohibits the maximum aggregate amount of investments of any savings association from exceeding the same 15% of its capital stock actually paid in and unimpaired and 15% of its unimpaired surplus as imposed by this Act on national banking associations and state member banks.

question:
SECTION 1. SHORT TITLE.

This Act may be cited as the ''Networking Electronically To Connect
Our Police Act of 2001'' or the ''NET COP Act''.

SEC. 2. FINDINGS; PURPOSES.

(a) Findings.--Congress finds that--
(1) Internet-based crime-fighting, investigatory, and
information-sharing technologies have proven to be extremely
useful to the law enforcement agencies that use them;
(2) the sharing of information and the dissemination of
criminal intelligence between and among Federal, State, and
local law enforcement agencies benefit the society at large by
making criminal investigations more inclusive and effective;
(3) the sharing of information between and among Federal,
State, and local law enforcement agencies allows these agencies
to find missing, neglected, abused, or abducted children, as
well as non-custodial parents seeking to evade their legal or
financial responsibilities; and
(4) police departments in rural areas of the country tend
to be underserved by these Internet-based technologies.
(b) Purposes.--The purposes of this Act are--
(1) to authorize the Department of Justice to make grants
to rural police departments for the purchase or upgrade of
computer equipment, and to pay for Internet access for crime-
fighting, investigatory, or information-sharing purposes;
(2) to reimburse police department officials or members
who, acting on behalf of their rural police departments and
using personal funds, have purchased computer equipment or paid
for Internet access for crime-fighting, investigatory, or
information-sharing purposes; and
(3) to require annual reports to Congress on the
concentration of police departments that have Internet access,
particularly those departments serving rural areas.

SEC. 3. GRANTS AUTHORIZED.

The Attorney General is authorized to award grants to rural police
departments to--
(1) enable those departments to gain access to the various
crime-fighting, investigatory, and information sharing
resources available on the Internet; and
(2) reimburse rural police department officials and members
for the cost of computer equipment or Internet access.

SEC. 4. USE OF FUNDS.

Grants awarded under this Act may be used--
(1) for the purchase of new or upgraded computer hardware
or software;
(2) to pay for Internet access; and
(3) to reimburse rural police departments that have paid
for computer equipment or Internet access out of the funds of
the department or department official or members, for some or
all of the costs associated with those purchases, as determined
by the Attorney General.

SEC. 5. APPLICATION.

Each eligible rural police department that desires a grant under
this Act shall submit an application to the Attorney General at such
time, in such manner, and accompanied by such information as the
Attorney General may reasonably require.

SEC. 6. GRANT PROGRAM CRITERIA.

(a) In General.--In awarding a grant under this Act, the Attorney
General shall--
(1) set criteria for determining which police departments
are currently underserved by crime-fighting, investigatory, or
information-sharing technologies available on the Internet, by
differentiating between police departments that do not have
Internet access, and those departments that have access but are
using outmoded, obsolete, or otherwise inadequate technology;
and
(2) determine what would constitute the minimum feasible
package of technologies required to enable those police
departments to use existing crime-fighting, investigatory, and
information-sharing technologies.
(b) Grant Limitations.--The Attorney General shall set limits for
maximum annual grants, based on determinations made under subsection
(a), for rural police departments that do not have Internet access, and
for those that do have access but are using inadequate technology.

SEC. 7. POLICE DEPARTMENT TECHNOLOGY ASSISTANCE DESK.

The Attorney General shall establish a Police Department Technology
Assistance Desk to offer advice to chiefs of police in rural police
departments regarding--
(1) the types of products to buy in order to achieve not
less than a minimum level of Internet service to access
existing crime-fighting, investigatory, and information-sharing
technologies; and
(2) technology upgrades for those police departments in
possession of outmoded or obsolete technology;
(3) preferred vendors; and
(4) any other information the Attorney General determines
to be necessary.

SEC. 8. REPORT TO CONGRESS.

The General Accounting Office, in consultation with the Attorney
General, shall annually report to Congress on the concentration of
police departments in the country that have Internet access, with
particular emphasis on the number and percentage of rural police
departments that lack Internet access, especially high-speed Internet
access.

SEC. 9. AUTHORIZATION OF APPROPRIATIONS.

There is authorized to be appropriated $500,000,000 for each of
fiscal years 2002 through 2007 to carry out this Act.
answer:
Networking Electronically To Connect Our Police Act of 2001 or NET COP Act - Authorizes the Attorney General to award grants to rural police departments to: (1) enable those departments to gain access to the various crime-fighting, investigatory, and information sharing resources available on the Internet; and (2) reimburse rural police department officials and members for the cost of computer equipment or Internet access.Allows grants awarded to be used: (1) for the purchase of new or upgraded computer hardware or software; (2) to pay for Internet access; and (3) to reimburse rural police departments that have paid for computer equipment or Internet access out of the funds of the department or department officials or members for some or all of the costs associated with those purchases, as determined by the Attorney General.Sets forth provisions regarding grant application requirements and grant program criteria.Directs the Attorney General to establish a Police Department Technology Assistance Desk to offer advice to chiefs of police in rural police departments.

question:
SECTION 1. SHORT TITLE.

This Act may be cited as the ''Orphan Products Extension Now
Accelerating Cures and Treatments Act of 2017'' or the ''OPEN Act''.

SEC. 2. EXTENSION OF EXCLUSIVITY PERIODS FOR A DRUG APPROVED FOR A NEW
INDICATION FOR A RARE DISEASE OR CONDITION.

(a) In General.--The Federal Food, Drug, and Cosmetic Act is
amended by inserting after section 505F of such Act (21 U.S.C. 355g)
the following:

''SEC. 505G. EXTENSION OF EXCLUSIVITY PERIODS FOR A DRUG APPROVED FOR A
NEW INDICATION FOR A RARE DISEASE OR CONDITION.

''(a) Designation.--
''(1) In general.--The Secretary shall designate a drug as
a drug approved for a new indication to prevent, diagnose, or
treat a rare disease or condition for purposes of granting the
extensions under subsection (b) if--
''(A) prior to approval of an application or
supplemental application for the new indication, the
drug was approved or licensed under section 505(c) of
this Act or section 351(a) of the Public Health Service
Act but was not so approved or licensed for the new
indication;
''(B)(i) the sponsor of the approved or licensed
drug files an application or a supplemental application
for approval of the new indication for use of the drug
to prevent, diagnose, or treat the rare disease or
condition; and
''(ii) the Secretary approves the application or
supplemental application; and
''(C) the application or supplemental application
for the new indication contains the consent of the
applicant to public notice under paragraph (4) with
respect to the designation of the drug.
''(2) Revocation of designation.--
''(A) In general.--Except as provided in
subparagraph (B), a designation under paragraph (1)
shall not be revoked for any reason.
''(B) Exception.--The Secretary may revoke a
designation of a drug under paragraph (1) if the
Secretary finds that the application or supplemental
application resulting in such designation contained an
untrue statement of material fact.
''(3) Notice to public.--The Secretary shall provide public
notice of the designation of a drug under paragraph (1).
''(b) Extension.--
''(1) In general.--If the Secretary designates a drug as a
drug approved for a new indication for a rare disease or
condition, as described in subsection (a)(1)--
''(A)(i) the 4-, 5-, and 7/2\-year periods
described in subsections (c)(3)(E)(ii) and
(j)(5)(F)(ii) of section 505, the 3-year periods
described in clauses (iii) and (iv) of subsection
(c)(3)(E) and clauses (iii) and (iv) of subsection
(j)(5)(F) of section 505, and the 7-year period
described in section 527, as applicable, shall be
extended by 6 months; or
''(ii) the 4- and 12-year periods described in
subparagraphs (A) and (B) of section 351(k)(7) of the
Public Health Service Act and the 7-year period
described in section 527, as applicable, shall be
extended by 6 months; and
''(B)(i) if the drug is the subject of a listed
patent for which a certification has been submitted
under subsection (b)(2)(A)(ii) or (j)(2)(A)(vii)(II) of
section 505 or a listed patent for which a
certification has been submitted under subsection
(b)(2)(A)(iii) or (j)(2)(A)(vii)(III) of section 505,
the period during which an application may not be
approved under section 505(c)(3) or section
505(j)(5)(B) shall be extended by a period of 6 months
after the date the patent expires (including any patent
extensions); or
''(ii) if the drug is the subject of a listed
patent for which a certification has been submitted
under subsection (b)(2)(A)(iv) or (j)(2)(A)(vii)(IV) of
section 505, and in the patent infringement litigation
resulting from the certification the court determines
that the patent is valid and would be infringed, the
period during which an application may not be approved
under section 505(c)(3) or section 505(j)(5)(B) shall
be extended by a period of 6 months after the date the
patent expires (including any patent extensions).
''(2) Relation to pediatric and qualified infectious
disease product exclusivity.--Any extension under paragraph (1)
of a period shall be in addition to any extension of the
periods under sections 505A and 505E of this Act and section
351(m) of the Public Health Service Act, as applicable, with
respect to the drug.
''(c) Limitations.--Any extension described in subsection (b)(1)
shall not apply if the drug designated under subsection (a)(1) has
previously received an extension by operation of subsection (b)(1).
''(d) Definition.--In this section, the term 'rare disease or
condition' has the meaning given to such term in section 526(a)(2).''.
(b) Application.--Section 505G of the Federal Food, Drug, and
Cosmetic Act, as added by subsection (a), applies only with respect to
a drug for which an application or supplemental application described
in subsection (a)(1)(B)(i) of such section 505G is first approved under
section 505(c) of such Act (21 U.S.C. 355(c)) or section 351(a) of the
Public Health Service Act (42 U.S.C. 262(a)) on or after the date of
the enactment of this Act.
(c) Conforming Amendments.--
(1) Relation to pediatric exclusivity for drugs.--Section
505A of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
355a) is amended--
(A) in subsection (b), by adding at the end the
following:
''(3) Relation to exclusivity for a drug approved for a new
indication for a rare disease or condition.--Notwithstanding
the references in paragraph (1) to the lengths of the
exclusivity periods after application of pediatric exclusivity,
the 6-month extensions described in paragraph (1) shall be in
addition to any extensions under section 505G.''; and
(B) in subsection (c), by adding at the end the
following:
''(3) Relation to exclusivity for a drug approved for a new
indication for a rare disease or condition.--Notwithstanding
the references in paragraph (1) to the lengths of the
exclusivity periods after application of pediatric exclusivity,
the 6-month extensions described in paragraph (1) shall be in
addition to any extensions under section 505G.''.
(2) Relation to exclusivity for new qualified infectious
disease products that are drugs.--Subsection (b) of section
505E of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
355f) is amended--
(A) by amending the subsection heading to read as
follows: ''Relation to Pediatric Exclusivity and
Exclusivity for a Drug Approved for a New Indication
for a Rare Disease or Condition.--''; and
(B) by striking ''any extension of the period under
section 505A'' and inserting ''any extension of the
periods under sections 505A and 505G, as applicable,''.
(3) Relation to pediatric exclusivity for biological
products.--Section 351(m) of the Public Health Service Act (42
U.S.C. 262(m)) is amended by adding at the end the following:
''(5) Relation to exclusivity for a biological product
approved for a new indication for a rare disease or
condition.--Notwithstanding the references in paragraphs
(2)(A), (2)(B), (3)(A), and (3)(B) to the lengths of the
exclusivity periods after application of pediatric exclusivity,
the 6-month extensions described in such paragraphs shall be in
addition to any extensions under section 505G.''.
answer:
Orphan Products Extension Now Accelerating Cures and Treatments Act of 2017 or the OPEN Act This bill amends the Federal Food, Drug, and Cosmetic Act to require the Department of Health and Human Services (HHS) to extend by six months the exclusivity period for a drug or biological product approved by the Food and Drug Administration (FDA) when the product is additionally approved to prevent, diagnose, or treat a new indication that is a rare disease or condition (also known as an orphan disease). HHS may revoke an extension if the application submitted to the FDA for the new indication contained an untrue material statement. HHS must notify the public of products that receive this extension and patents related to those products. Products may receive only one extension under this bill. Extensions under this bill are in addition to other extensions. The bill applies only to products approved after enactment of this bill for a new indication that is a rare disease or condition.